Genetic Technologies (ASX:GTG, NASDAQ:GENE) has increased the number of BREVAGen breast cancer test samples returned in the June 2014 quarter by 37% over the March 2014 quarter.
This represents a return to levels achieved in late 2013.
It also brings the total samples received to 3,935 for the 2014 financial year, more than double the 1,547 received in the previous corresponding period.
The company is also on target to release the next generation BREVAGen test in the fourth quarter of this year.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.